advertisement
Siesky B 28
Showing records 1 to 25 | Display all abstracts from Siesky B99068 Choroidal Thickness and Primary Open-Angle Glaucoma-A Narrative Review
Verticchio Vercellin A
Journal of clinical medicine 2022; 11:
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Shin JD
Acta Ophthalmologica 2022; 100: e377-e385
99304 Glaucoma Treatment Outcomes in Open-Angle Glaucoma Patients of African Descent
Siesky B
Journal of Glaucoma 2022; 31: 479-487
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Wolf AT; Wolf AT
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
99068 Choroidal Thickness and Primary Open-Angle Glaucoma-A Narrative Review
Harris A
Journal of clinical medicine 2022; 11:
99304 Glaucoma Treatment Outcomes in Open-Angle Glaucoma Patients of African Descent
Harris A
Journal of Glaucoma 2022; 31: 479-487
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Harris A
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Wolf AT; Wolf AT
Acta Ophthalmologica 2022; 100: e377-e385
99304 Glaucoma Treatment Outcomes in Open-Angle Glaucoma Patients of African Descent
Belamkar A
Journal of Glaucoma 2022; 31: 479-487
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Harris A
Acta Ophthalmologica 2022; 100: e377-e385
99068 Choroidal Thickness and Primary Open-Angle Glaucoma-A Narrative Review
Stoner AM
Journal of clinical medicine 2022; 11:
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Oddone F
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Verticchio Vercellin A
Acta Ophthalmologica 2022; 100: e377-e385
99304 Glaucoma Treatment Outcomes in Open-Angle Glaucoma Patients of African Descent
Zukerman R
Journal of Glaucoma 2022; 31: 479-487
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Siesky B
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
99068 Choroidal Thickness and Primary Open-Angle Glaucoma-A Narrative Review
Oddone F
Journal of clinical medicine 2022; 11:
99304 Glaucoma Treatment Outcomes in Open-Angle Glaucoma Patients of African Descent
Horn A
Journal of Glaucoma 2022; 31: 479-487
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Verticchio Vercellin A
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
99068 Choroidal Thickness and Primary Open-Angle Glaucoma-A Narrative Review
Mendoza KA
Journal of clinical medicine 2022; 11:
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Siesky B; Rowe LW
Acta Ophthalmologica 2022; 100: e377-e385
98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Ciulla TA
Expert Opinion on Therapeutic Targets 2022; 26: 5-12
99068 Choroidal Thickness and Primary Open-Angle Glaucoma-A Narrative Review
Siesky B
Journal of clinical medicine 2022; 11:
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Rowe LW
Acta Ophthalmologica 2022; 100: e377-e385
99304 Glaucoma Treatment Outcomes in Open-Angle Glaucoma Patients of African Descent
Vercellin AV
Journal of Glaucoma 2022; 31: 479-487
98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Packles M
Acta Ophthalmologica 2022; 100: e377-e385
